Company Profile
Ironwood Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Ironwood Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Ironwood Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Ironwood Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Ironwood Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
IRWD is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Ironwood's catalysts are Linzess execution, GI commercial stability, and any pipeline or partnership update that clarifies the next growth vector. The company still needs the core franchise to stay durable.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2B Studies
Source: Ironwood Pharmaceuticals
- 03
Microbia Appoints Halley Gilbert as Vice President, General Counsel
Source: Ironwood Pharmaceuticals
- 04
Microbia Announces Name Change to Ironwood Pharmaceuticals
Source: Ironwood Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.